BACKGROUND: Troxerutin (TRX) has a beneficial effect on blood viscosity and platelet aggregation, and is currently used for the treatment of chronic varicosity. Recently, TRX can improve lipid abnormalities, glucose intolerance and oxidative stress in high-fat diet-induced metabolic disorders. In this study, we tested the effect of TRX on metabolic syndrome-associated disorders using a non-obese model of metabolic syndrome-the Hereditary Hypertriglyceridaemic rats (HHTg). METHODS: Adult male HHTg rats were fed standard diet without or with TRX (150 mg/kg bwt/day for 4 weeks). RESULTS: Compared to untreated rats, TRX supplementation in HHTg rats decreased serum glucose (p<0.05) and insulin (p<0.05). Although blood lipids were not affected, TRX decreased hepatic cholesterol concentrations (p<0.01) and reduced gene expression of HMGCR, SREBP2 and SCD1 (p<0.01), involved in cholesterol synthesis and lipid homeostasis. TRX-treated rats exhibited decreased lipoperoxidation and increased activity of antioxidant enzymes SOD and GPx (p<0.05) in the liver. In addition, TRX supplementation increased insulin sensitivity in muscles and epididymal adipose tissue (p<0.05). Elevated serum adiponectin (p<0.05) and decreased muscle triglyceride (p<0.05) helped improve insulin sensitivity. Among the beneficial effects of TRX were changes to cytochrome P450 family enzymes. Hepatic gene expression of CYP4A1, CYP4A3 and CYP5A1 (p<0.01) decreased, while there was a marked elevation in gene expression of CYP1A1 (p<0.01). CONCLUSION: Our results indicate that TRX improves hepatic lipid metabolism and insulin sensitivity in peripheral tissues. As well as ameliorating oxidative stress, TRX can reduce ectopic lipid deposition, affect genes involved in lipid metabolism, and influence the activity of CYP family enzymes.

• MeSH
• glukosa metabolismus   MeSH
• glykogen metabolismus   MeSH
• hydroxyethylrutosid analogy a deriváty   terapeutické užití   MeSH
• hypolipidemika terapeutické užití   MeSH
• inbrední kmeny potkanů MeSH
• inzulinová rezistence MeSH
• kosterní svaly metabolismus   MeSH
• krysa rodu Rattus MeSH
• kvantitativní polymerázová řetězová reakce MeSH
• metabolický syndrom farmakoterapie   MeSH
• metabolismus lipidů účinky léků   MeSH
• modely nemocí na zvířatech MeSH
• oxidační stres účinky léků   MeSH
• transkriptom účinky léků   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• glukosa MeSH
• glykogen MeSH
• hydroxyethylrutosid MeSH
• hypolipidemika MeSH
• troxerutin MeSH Prohlížeč

The objective of the study was to estimate the association of pregnant women with varicose veins of lower extremities (VVLE) and the possible risk for adverse birth outcomes and among them different congenital abnormalities (CAs) in their children. Prospectively and medically recorded VVLE were evaluated in 332 pregnant women who delivered infants with CA (case group) and 566 pregnant women with VVLE who delivered infants without CA (control group) and matched to cases were compared in the population-based data set of the Hungarian Case-Control Surveillance System of Congenital Abnormalities, 1980-1996. About one-quarter of pregnant women had chronic VVLE while new onset VVLE occurred in the rest of pregnant women. There was no higher risk for adverse birth outcomes of pregnant women with VVLE, in fact the rate of preterm birth and low birth weight was somewhat lower than in the newborns of pregnant women without VVLE. The comparison of VVLE occurrence in pregnant women who had offspring with 21 different CA groups and in pregnant women who later delivered babies without CA showed a higher risk only for pectus excavatum, a mild CA. In conclusion, VVLE in pregnant women does not associate with obvious hazard for their fetuses.

• MeSH
• antikoagulancia škodlivé účinky   MeSH
• dospělí MeSH
• hrudník vpáčený epidemiologie   etiologie   MeSH
• hydroxyethylrutosid škodlivé účinky   analogy a deriváty   MeSH
• kardiovaskulární komplikace v těhotenství farmakoterapie   epidemiologie   MeSH
• lidé MeSH
• logistické modely MeSH
• novorozenec MeSH
• prospektivní studie MeSH
• retrospektivní studie MeSH
• rizikové faktory MeSH
• studie případů a kontrol MeSH
• těhotenství MeSH
• varixy farmakoterapie   epidemiologie   MeSH
• vrozené vady epidemiologie   etiologie   MeSH
• výsledek těhotenství * MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• novorozenec MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Maďarsko epidemiologie   MeSH
• Názvy látek
• antikoagulancia MeSH
• hydroxyethylrutosid MeSH
• troxerutin MeSH Prohlížeč

The effect of 7-mono-hydroxyethylrutoside and its combination with acetylsalicylic acid was evaluated in a controlled clinical trial, performed in 105 patients with obliterative atherosclerosis of the lower limbs, and using non-invasive measurement of peripheral haemodynamic parameters--blood flow during reactive hyperaemia and ankle systolic blood pressure. Patients, randomized into three groups, received either placebo or 7-mono-hydroxyethylrutoside alone or in combination with acetylsalicylic acid for 12 months. The placebo group showed a decrease in maximum calf blood flow and a decrease in ankle systolic pressure. Administration of 7-mono-hydroxyethylrutoside did not lead to any significant changes in systolic pressure but there was a decrease in the maximum calf blood flow. There were no statistically significant changes in patients receiving the 7-mono-hydroxyethylrutoside and acetylsalicylic acid combination who, by contrast, showed a tendency to increased values of the parameters measured.

• MeSH
• analgetika aplikace a dávkování   MeSH
• antikoagulancia aplikace a dávkování   MeSH
• arteriosclerosis obliterans farmakoterapie   MeSH
• Aspirin aplikace a dávkování   analogy a deriváty   MeSH
• bérec krevní zásobení   MeSH
• dospělí MeSH
• hemodynamika účinky léků   MeSH
• hydroxyethylrutosid aplikace a dávkování   analogy a deriváty   MeSH
• ischemie farmakoterapie   MeSH
• klinické zkoušky jako téma MeSH
• kombinovaná farmakoterapie MeSH
• lidé středního věku MeSH
• lidé MeSH
• pletysmografie MeSH
• rutin analogy a deriváty   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH
• Názvy látek
• aloxiprin MeSH Prohlížeč
• analgetika MeSH
• antikoagulancia MeSH
• Aspirin MeSH
• hydroxyethylrutosid MeSH
• rutin MeSH
• troxevasin MeSH Prohlížeč

The endothelo-protective activity of a series of low-molecular oxygen-derived free radical scavengers (OFRS) was tested in rats. A model of endothelaemia provoked by intravenous administration of hydrogen peroxide was used. With each OFRS the activity in the hydrogen peroxide model was compared with that in the less specific model using the provocation by citrate as a calcium chelating agent. Relatively unspecific but biologically important OFRS, ascorbic acid, tocopherol, troxerutin and glutathione were tested in the first phase of the study. A marked optimum of endothelo-protective activity was shown with all agents, the optimum against hydrogen peroxide having been observed at doses from 3 to 50 times lower than against citrate. Ascorbic acid, troxerutin and the combination of both were also tested in another model based on leg ischaemia produced by ligature of the common femoral artery. Without OFRS, a marked increase of endothelaemia was observed after 30-60 min ischaemia showing a second peak after the release of the ligature. This second peak was completely abolished by the preventive administration of OFRS in a dose which was also effective in the hydrogen peroxide model.

• MeSH
• alfa-tokoferol * analogy a deriváty   MeSH
• antikoagulancia farmakologie   MeSH
• arteria femoralis fyziologie   MeSH
• Aspirin farmakologie   MeSH
• endotel účinky léků   fyziologie   MeSH
• heparin farmakologie   MeSH
• hydroxyethylrutosid analogy a deriváty   farmakologie   MeSH
• inbrední kmeny potkanů MeSH
• kinetika MeSH
• koronární nemoc patofyziologie   MeSH
• krysa rodu Rattus MeSH
• kyselina askorbová farmakologie   MeSH
• kyselina mléčná MeSH
• kyselina pyrohroznová MeSH
• laktáty farmakologie   MeSH
• perfuze MeSH
• peroxid vodíku toxicita   MeSH
• pyruváty farmakologie   MeSH
• rutin analogy a deriváty   MeSH
• tokoferoly MeSH
• vitamin E analogy a deriváty   farmakologie   MeSH
• volné radikály MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• alfa-tokoferol * MeSH
• antikoagulancia MeSH
• Aspirin MeSH
• heparin MeSH
• hydroxyethylrutosid MeSH
• kyselina askorbová MeSH
• kyselina mléčná MeSH
• kyselina pyrohroznová MeSH
• laktáty MeSH
• peroxid vodíku MeSH
• pyruváty MeSH
• rutin MeSH
• tokoferoly MeSH
• troxerutin MeSH Prohlížeč
• vitamin E MeSH
• volné radikály MeSH

Clinical and experimental evidence support the metabolic aetiology of diabetic microangiopathy. This paves the way for its management by transplantation of endocrine pancreas. In an informative article, the authors attempts to conceptualize their position concerning indications for pancreas transplantation and offer a review of their own experimental studies, a prerequisite before actual clinical application.

• MeSH
• diabetické angiopatie terapie   MeSH
• diabetické nefropatie terapie   MeSH
• fixní kombinace léků farmakologie   MeSH
• fluoresceiny farmakologie   MeSH
• hydroxyethylrutosid analogy a deriváty   farmakologie   MeSH
• kumariny farmakologie   MeSH
• lidé MeSH
• organortuťnaté sloučeniny farmakologie   MeSH
• psi MeSH
• rejekce štěpu účinky léků   MeSH
• tetracyklin farmakologie   MeSH
• transplantace Langerhansových ostrůvků * MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• psi MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• fixní kombinace léků MeSH
• fluoresceiny MeSH
• hydroxyethylrutosid MeSH
• kumariny MeSH
• mercurascan MeSH Prohlížeč
• organortuťnaté sloučeniny MeSH
• tetracyklin MeSH
• Venalot MeSH Prohlížeč

• MeSH
• cholesterol krev   MeSH
• hydroxyethylrutosid farmakologie   MeSH
• kyselina askorbová metabolismus   moč   MeSH
• metabolická clearance účinky léků   MeSH
• morčata MeSH
• rutin analogy a deriváty   MeSH
• zvířata MeSH
• Check Tag
• morčata MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• cholesterol MeSH
• hydroxyethylrutosid MeSH
• kyselina askorbová MeSH
• rutin MeSH